Ridinilazole: a novel, narrow‐spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile

Clostridium (Clostridioides) difficile infection (CDI) remains an urgent threat to patients in health systems worldwide. Recurrent CDI occurs in up to 30% of cases due to sustained dysbiosis of the gut microbiota which normally protects against CDI. Associated costs of initial and recurrent episodes...

Descripción completa

Detalles Bibliográficos
Autores principales: Collins, Deirdre A, Riley, Thomas V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541751/
https://www.ncbi.nlm.nih.gov/pubmed/35119124
http://dx.doi.org/10.1111/lam.13664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541751/
https://www.ncbi.nlm.nih.gov/pubmed/35119124
http://dx.doi.org/10.1111/lam.13664

Ejemplares similares